Is Theriva Biologics Inc. (TOVX) overvalued? · rev $300.0K
Theriva Biologics Inc. (TOVX) is a biotechnology company listed on NYSE MKT.
This page asks whether Theriva Biologics Inc. (TOVX) looks expensive on cached numbers — not a short thesis.
Latest reported TOVX revenue for 2026-06-30 was $300.0K. Net income was -$5.3M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. TOVX currently screens at market cap $12.4M.
TOVX currently screens at market cap $12.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TOVX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TOVX stock page for the full model, not this heading.
Not investment advice.